Kraig Biocraft Labs Files S-1/A with Updated Financials

TL;DR

KBLG S-1/A filed: $1.1M assets, $1.3M liabs as of 9/30/24. Watch closely.

AI Summary

Kraig Biocraft Laboratories, Inc. filed an S-1/A on December 9, 2024, detailing its financial status. As of September 30, 2024, the company reported $1.1 million in total assets, with $1.0 million in current assets. Total liabilities stood at $1.3 million, including $0.3 million in current liabilities. The company's fiscal year ends on December 31.

Why It Matters

This filing provides an updated snapshot of Kraig Biocraft Laboratories' financial health, crucial for investors to assess the company's financial position and potential risks.

Risk Assessment

Risk Level: medium — The company has more liabilities than assets as of the filing date, indicating potential financial strain.

Key Numbers

• $1.1M — Total Assets (As of September 30, 2024, indicating the company's total resources.)
• $1.3M — Total Liabilities (As of September 30, 2024, showing the company's total obligations.)
• $1.0M — Current Assets (As of September 30, 2024, representing assets expected to be converted to cash within a year.)
• $0.3M — Current Liabilities (As of September 30, 2024, representing obligations due within a year.)

Key Players & Entities

• Kraig Biocraft Laboratories, Inc. (company) — Filer of the S-1/A
• 2024-12-09 (date) — Filing date of the S-1/A
• $1.1 million (dollar_amount) — Total assets as of September 30, 2024
• $1.0 million (dollar_amount) — Current assets as of September 30, 2024
• $1.3 million (dollar_amount) — Total liabilities as of September 30, 2024
• $0.3 million (dollar_amount) — Current liabilities as of September 30, 2024
• 2024-09-30 (date) — Reporting date for financial figures
• 2023-12-31 (date) — Previous fiscal year end

FAQ

Key Financial Figures

• $5.25 — on an assumed initial offering price of $5.25 per Unit, the midpoint of the anticipat
• $4.25 — icipate a public offering price between $4.25 and $6.25 per Unit. Each Unit consist
• $6.25 — public offering price between $4.25 and $6.25 per Unit. Each Unit consists of 1 sha
• $0.11 — Common Stock as quoted on the OTCQB was $0.11 per share. There is no established trad
• $40 million — which they committed to purchase up to $40 million worth of product. This partnership will

Filing Documents

• forms-1a.htm (S-1/A) — 3621KB
• ex23-1.htm (EX-23.1) — 4KB
• logo_001.jpg (GRAPHIC) — 2KB
• logo_004.jpg (GRAPHIC) — 2KB
• logo_002.jpg (GRAPHIC) — 1KB
• logo_003.jpg (GRAPHIC) — 2KB
• ex23-1_001.jpg (GRAPHIC) — 35KB
• form10-k_006.jpg (GRAPHIC) — 8KB
• 0001493152-24-049282.txt ( ) — 14909KB
• kblb-20240930.xsd (EX-101.SCH) — 68KB
• kblb-20240930_cal.xml (EX-101.CAL) — 60KB
• kblb-20240930_def.xml (EX-101.DEF) — 339KB
• kblb-20240930_lab.xml (EX-101.LAB) — 539KB
• kblb-20240930_pre.xml (EX-101.PRE) — 456KB
• forms-1a_htm.xml (XML) — 3302KB

Underwriting

Underwriting Discounts (1)(2) $ $ $ Proceeds to the Company (before expenses) $ $ $ (1) We refer you to the section of this prospectus entitled "Underwriting" for additional information regarding underwriter compensation. (2) We estimate the total expenses payable by us, excluding the underwriting discount, will be approximately $[]. (3) Based on an assumed price to the public in this Offering of $5.25 per Unit, the midpoint of the price range set forth on the cover page of this prospectus. We have granted the underwriters a 45-day option to purchase up to an additional 285,715 shares of Common Stock and/or Purchase Warrants to purchase 285,715 shares of Common Stock from us at the assumed public offering price, less the underwriting discount, to cover over-allotments, if any, within forty-five (45) days from the date of this prospectus. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. The underwriters expect to deliver the shares of Common Stock and Purchase Warrants to purchasers on or about [], 2024, subject to customary closing conditions, including that, upon the closing of the offering, the Common Stock would qualify for listing on a national exchange. Sole-Book Running Manager Maxim Group LLC The date of this prospectus is December 9, 2024 EXPLANATORY NOTE We are filing this Amendment No. 16 to our registration statement on Form S-1, initially filed on June 2, 2020, as amended on August 24, 2020, February 8, 2021, February 18, 2021, May 26, 2021, August 25, 2021, December 3, 2021, April 14, 2022, May 25, 2022, December 1, 2022, April 14, 2023, April 27, 2023, May 9, 2023, June 6, 2023, September 1, 2023, November 22, 2023 (File No. 333-238883) (as amended, the "Registration Statement") , to include information contained in the registra

RISK FACTORS

RISK FACTORS 16 DISCLOSURE REGARDING FORWARD-LOOKING STATEMENTS 30

USE OF PROCEEDS

USE OF PROCEEDS 31 DIVIDEND POLICY 31 CAPITALIZATION 32

DILUTION

DILUTION 33 MARKET PRICE AND DIVIDENDS ON OUR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS 34

BUSINESS

BUSINESS 37 MANAGEMENT DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 48 CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE 57 DIRECTORS AND EXECUTIVE OFFICERS 57

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 62

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS 65 CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE 67

DESCRIPTION OF SECURITIES

DESCRIPTION OF SECURITIES 71

DESCRIPTION OF SECURITIES THAT WE ARE OFFERING

DESCRIPTION OF SECURITIES THAT WE ARE OFFERING 77 SHARES ELIGIBLE FOR FUTURE SALE 72 CERTAIN U.S. FEDERAL INCOME TAX CONSIDERATIONS 73

UNDERWRITING

UNDERWRITING 75 DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES 79 LEGAL MATTERS 79 EXPERTS 79 WHERE YOU CAN FIND MORE INFORMATION 79 PART II 80 INDEX TO FINANCIAL STATEMENTS F-1 3 About this Prospectus We and the underwriters have not authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectuses prepared by us or on our behalf or to which we have referred you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the Units offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. We are not making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted or where the person making the offer or sale is not qualified to do so or to any person to whom it is not permitted to make such offer or sale. The information contained in this prospectus is current only as of the date on the front cover of the prospectus. Our business, financial condition, results of operations and prospects may have changed since that date. Persons who come into possession of this prospectus and any applicable free writing prospectus in jurisdictions outside the United States are required to inform themselves about and to observe any restrictions as to this offering and the distribution of this prospectus and any such free writing prospectus applicable to that jurisdiction. See "Underwriting" for additional information on these restrictions. Industry and Market Data Unless otherwise indicated, information in this prospectus concerning economic conditions, our industry, our markets and our competitive position is based on a variety of sources, including information from third-party industry analysts and publications and our own estimates and res

View Full Filing

View this S-1/A filing on SEC EDGAR